Cortexyme Announces Third Quarter 2020 Financial Results and Provides Business UpdateBusiness Wire • 11/12/20
Cortexyme Presents an Update and Baseline Data from the Phase 2/3 GAIN Trial of Atuzaginstat at CTAD 2020, the Clinical Trials on Alzheimer's Disease ConferenceBusiness Wire • 11/05/20
Cortexyme Announces GAIN Trial of Atuzaginstat in Alzheimer’s Disease Has Exceeded Study Enrollment Target of 570 PatientsBusiness Wire • 09/24/20
Cortexyme to Present at the H.C. Wainwright 22nd Annual Global Investment Conference on September 14, 2020Business Wire • 09/09/20
Cortexyme Announces Issuance of Composition of Matter Patent for Atuzaginstat by the U.S. Patent and Trademark OfficeBusiness Wire • 08/27/20
Cortexyme Announces Second Quarter 2020 Financial Results and Provides Business UpdateBusiness Wire • 08/17/20
Cortexyme Announces GAIN Trial of Atuzaginstat in Alzheimer’s Disease Has Reached Enrollment Milestone of 500 PatientsBusiness Wire • 08/14/20
Cortexyme Announces Webcasts of Investor Conference Presentations in August 2020Business Wire • 08/06/20
Cortexyme to Participate in Virtual Fireside Chat Hosted by LifeSci Capital on July 30, 2020Business Wire • 07/29/20
Cortexyme Presents Data Linking P. gingivalis Infection to Cardiovascular Disease Severity and Alzheimer's Disease, Along With Evidence That Treatment With Atuzaginstat (COR388) Improves Biomarkers Associated With Both DiseasesBusiness Wire • 07/28/20
Cortexyme Announces Upcoming Data Presentations at the Alzheimer’s Association International Conference 2020Business Wire • 07/22/20